The Directorate General of Foreign Trade in India has laid down the conditions for import and export of human biological samples for commercial purposes recently.
As per the policy, “export and import should be permitted by “customs authorities at the port of entry/exit without prior approvals (import licence/export permit) from any other government agency, provided the concerned Indian company/ agency submits an undertaking that they are following and will follow all the applicable rules, regulations and procedures for safe transfer and disposal of the samples."
The norms are a major relief for biotech companies, contract research organizations (CROs), and research centers as the earlier licensing process required a great deal of paper work, according to a posting on the website of Brand India Pharma, a unit of Pharmexcil (The Pharmaceutical Export Promotion Council of India).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze